ClinicalTrials.gg
RecruitingNCT07290205REMAZUpdated Apr 2, 2026

Remimazolam NeuroImaging

An Early Phase 1 interventional study of Remimazolam and Peripheral Nerve Stimulation in Anesthesia, Pain and Remimazolam, sponsored by Keith M Vogt. Recruiting at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Keith M Vogt · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
1,333rd of 2,564
60 · median 66
Started
2026
with 114 others
Phase 1
206 of 2,886
28 open now
Primary completion
2027-12
later than 260 of 392 live
Registered
2,796th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,333rd largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 115 that started in 2026, is one of 206 in phase 1, reaches primary completion later than 260 of the 392 other live ones, and was the 2,796th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task

03

Conditions studied

  • Anesthesia
  • Pain
  • Remimazolam

Browse trials for

Keywords

  • Remimazolam
  • functional MRI
  • electric nerve stimulation
  • sedation
  • functional connectivity
  • memory
  • pain
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-59 years of age, who:
  • have none of the specific exclusion criteria
  • have a valid email address and valid phone number throughout the study
  • free from any non-MRI compatible implants

Exclusion criteria

Exclusion Criteria:

  • are pregnant or attempting to conceive
  • (BMI) > 35
  • significant memory impairment or hearing loss
  • sleep apnea
  • chronic pain or frequently taking pain medication (including tramadol)
  • chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)
  • neurologic disease, including seizures and tremor
  • psychiatric diagnoses, including anxiety, depression, panic, or PTSD
  • a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease
  • severe claustrophobia or MRI intolerance
  • have metal implants or non-removable metal piercings
  • having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication
  • are allergic to dextran
  • daily alcohol or heavy alcohol use; history of alcohol abuse
  • current daily smoker
  • regular or recent marijuana use (including prescribed/medical marijuana)
  • illicit drug use, i.e., street drugs
  • regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Remimazolam+Pain

    Single-arm study. All subjects receive remimazolam and painful electric nerve stimulation, while being imaged with MRI, as described in the interventions.

    Drug: Remimazolam · Device: Peripheral Nerve Stimulation

Interventions

  • Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.

  • DevicePeripheral Nerve Stimulation

    Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.

06

What researchers measure

Primary outcomes

  1. Explicit memory performance

    Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance. Cross-condition comparisons will be the main effect of interest, comparing no drug to remimazolam.

    Time frame: Day/Visit 2: 12-36 hours after day 1 session

  2. subjective pain ratings

    Numerical ratings of pain intensity and unpleasantness will be obtained after each experimental period involving repeated noxious stimulation. Values will be on a 0-10 scale, with 0 representing none and 10 representing the worst possible rating.

    Time frame: Day/Visit 1: immediately after no-drug condition MRI scan and immediately after remimazolam condition MRI scan

Secondary outcomes

  1. functional magnetic resonance imaging activation of memory encoding task

    Event-related blood-oxygen level dependent (BOLD) Magnetic Resonance Imaging (MRI) responses will be determined for each experimental item presented, revealing localized changes in blood flow, which correlate to increased neuronal activity. These will be averaged across the multiple repetitions of memory-encoding experimental events, creating an anatomical map of Z-scores. Cross-condition comparisons will be the main effect of interest, comparing no drug to remimazolam.

    Time frame: Day/Visit 1: during no-drug condition MRI scan and during remimazolam MRI scan

  2. functional magnetic resonance imaging activation of the response to noxious stimulation

    Event-related blood-oxygen level dependent (BOLD) Magnetic Resonance Imaging (MRI) responses will be determined for each experimental item presented, revealing localized changes in blood flow, which correlate to increased neuronal activity. These will be averaged across the multiple repetitions of noxious stimulation events, creating an anatomical map of Z-scores. Cross-condition comparisons will be the main effect of interest, comparing no drug to remimazolam.

    Time frame: Day/Visit 1: during no-drug condition MRI scan and during remimazolam MRI scan

  3. Functional connectivity

    Whole-brain functional connectivity will be determined in each condition (no-drug and remimazolam). This generates a matrix of cross-correlation values. Cross-condition comparisons will be the main effect of interest, comparing no drug to remimazolam.

    Time frame: Day/Visit 1: during no-drug condition MRI scan, during remimazolam MRI scan

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data to share: age, height, weight, sex pain intensity \& unpleasantness, ratings observer assessment of sedation at the targeted drug dose Behavioral performance data for long-term memory structural and functional MRI images

Supporting information: Study protocol, Informed consent form

Time frame: After analysis is complete and results have been published, all the above data will be shared in de-identified format, linked together by an assigned subject number.

Access criteria: Data will be shared via a publicly-accessible online platform that allows user download at no cost.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 20 months is below that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 18, 2025
StartActual
Mar 27, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 2, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290205
Lead sponsor
Keith M Vogt
Responsible party
Keith M Vogt (Associate Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Dec 18, 2025
Start date
Mar 27, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Keith M Vogt, MD, PhD
Contact
kev18@pitt.edu
4126473147
Keith M Vogt, MD, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion